Last updated: April 24, 2026
Who Supplies Giapreza (angiotensin II) to the Market?
What companies supply Giapreza?
Giapreza (angiotensin II) is marketed by Janssen Biotech, Inc. (a Johnson & Johnson company). Janssen is also the listed marketing authorization holder for the brand in the US.
Key sourcing roles (brand-level):
- Marketing authorization / brand owner: Janssen Biotech, Inc.
- Product supply: Janssen Biotech, Inc. (brand distribution in the US is tied to the Janssen labeling and commercial supply chain)
Is the drug sourced from multiple suppliers?
No supplier network is disclosed at the brand label level. For business planning tied to clinical supply, procurement, or manufacturing contingency, the public-facing supplier information for Giapreza is limited to the brand’s marketing/labeling entity rather than named API or finished-goods manufacturers.
Where is Giapreza produced (public manufacturer listings)?
The publicly available brand documentation for Giapreza centers on the labeling entity and does not provide a complete, transparent list of:
- API manufacturers
- finished-dose manufacturing sites
- contract manufacturing organizations (CMOs)
- toll manufacturing arrangements
For supplier due diligence, the practical procurement-facing “supplier” for Giapreza in the market is therefore Janssen Biotech, Inc., with manufacturing sub-sources not consistently enumerated in public label text.
Supply Chain Facts Used for Procurement Screening
Brand owner and labeling entity
| Item |
Value |
| Brand |
Giapreza |
| Active ingredient |
Angiotensin II |
| Marketing / labeling entity (US) |
Janssen Biotech, Inc. |
Regulatory anchor for “who supplies the brand”
The US label ties commercial responsibility to the marketing entity: Janssen Biotech, Inc. (J&J). This is the authoritative supplier contact point for wholesale distribution and direct procurement channels.
Key Takeaways
- Janssen Biotech, Inc. is the public-facing supplier entity for Giapreza in the US through the brand label and commercialization responsibility.
- Public sources do not reliably enumerate named API or CMO manufacturers for Giapreza at the brand level, so supplier mapping beyond Janssen requires label-to-regulatory filing traceability rather than consumer-label text.
- For procurement and contingency planning, treat Janssen Biotech, Inc. as the primary supplier-of-record for the finished brand unless contract-level documentation provides sub-supplier disclosure.
FAQs
1) Who is the supplier-of-record for Giapreza in the US?
Janssen Biotech, Inc. is the marketing and labeling entity associated with Giapreza in the US.
2) Are API manufacturers listed on Giapreza labeling?
Not in a consistent, complete way in publicly accessible label text.
3) Can I treat Janssen as the finished-goods supplier?
Yes for market procurement tied to the labeled product, because the brand’s commercialization responsibility in the US is held by Janssen Biotech, Inc.
4) Do public sources list multiple manufacturers for Giapreza?
Not at the brand level in a way that supports an actionable multi-supplier procurement plan.
5) Where should supply risk screening start?
From Janssen Biotech, Inc. as the brand’s marketing and labeling entity, then proceed through regulatory and procurement documentation for any disclosed manufacturing sites.
References (APA)
[1] Janssen Biotech, Inc. (n.d.). Giapreza (angiotensin II) prescribing information. U.S. Food and Drug Administration (FDA) label.
